A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202

被引：0
作者：
Syma Iqbal
Cathryn Rankin
Heinz-Josef Lenz
Philip J. Gold
Syed A. Ahmad
Anthony B. El-Khoueiry
Michael J. Messino
Randall F. Holcombe
Charles D. Blanke
机构：
[1] University of Southern California,Norris Comprehensive Cancer Center
[2] Southwest Oncology Group Statistical Center,Barrett Center, Department of Surgery
[3] Swedish Cancer Institute,undefined
[4] University of Cincinnati,undefined
[5] Southeast Cancer Control Consortium,undefined
[6] Inc. CCOP,undefined
[7] Cancer Care of WNC,undefined
[8] University of California at Irvine,undefined
[9] Chao Family CCC,undefined
[10] University of British Columbia,undefined
[11] and British Columbia Cancer Agency,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Gemcitabine; Capecitabine; Cholangiocarcinoma; Gallbladder; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1595 / 1602
页数：7
相关论文
共 50 条
  • [41] Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group
    Xiros, N
    Papacostas, P
    Economopoulos, T
    Samelis, G
    Efstathiou, E
    Kastritis, E
    Kalofonos, H
    Onyenatum, A
    Skarlos, D
    Bamias, A
    Gogas, H
    Bafaloukos, D
    Samantas, E
    Kosmidis, P
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 773 - 779
  • [42] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Heloisa P. Soares
    Soley Bayraktar
    Marcelo Blaya
    Gilberto Lopes
    Jaime Merchan
    Jessica Macintyre
    Carlos Mayo
    Mark R. Green
    Orlando Silva
    Joe Levi
    Gail Walker
    Caio M. Rocha-Lima
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 839 - 845
  • [43] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Soares, Heloisa P.
    Bayraktar, Soley
    Blaya, Marcelo
    Lopes, Gilberto
    Merchan, Jaime
    Macintyre, Jessica
    Mayo, Carlos
    Green, Mark R.
    Silva, Orlando
    Levi, Joe
    Walker, Gail
    Rocha-Lima, Caio M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 839 - 845
  • [44] The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study
    Weick, JK
    Crowley, JJ
    Hussein, MA
    Moore, DF
    Barlogie, B
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 117 - 121
  • [45] The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study
    James K. Weick
    John J. Crowley
    Mohamed A. Hussein
    Dennis F. Moore
    Bart Barlogie
    Investigational New Drugs, 2002, 20 : 117 - 121
  • [46] A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
    Oh, Do-Youn
    Cha, Yongjun
    Choi, In-Sil
    Yoon, So-Young
    Choi, In Keun
    Kim, Jee Hyun
    Oh, Sang Cheul
    Kim, Chang Duck
    Kim, Jae Sun
    Bang, Yung-Jue
    Kim, Yeul Hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 527 - 536
  • [47] Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
    Park, Ji Soo
    Jeung, Hei-Cheul
    Rha, Sun Young
    Ahn, Joong Bae
    Kang, Beodeul
    Chon, Hong Jae
    Hong, Min Hee
    Lim, Seungtaek
    Yang, Woo Ick
    Nam, Chung Mo
    Chung, Hyun Cheol
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 799 - 808
  • [48] Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
    Ji Soo Park
    Hei-Cheul Jeung
    Sun Young Rha
    Joong Bae Ahn
    Beodeul Kang
    Hong Jae Chon
    Min Hee Hong
    Seungtaek Lim
    Woo Ick Yang
    Chung Mo Nam
    Hyun Cheol Chung
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 799 - 808
  • [49] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
    Hezel, A. F.
    Noel, M. S.
    Allen, J. N.
    Abrams, T. A.
    Yurgelun, M.
    Faris, J. E.
    Goyal, L.
    Clark, J. W.
    Blaszkowsky, L. S.
    Murphy, J. E.
    Zheng, H.
    Khorana, A. A.
    Connolly, G. C.
    Hyrien, O.
    Baran, A.
    Herr, M.
    Ng, K.
    Sheehan, S.
    Harris, D. J.
    Regan, E.
    Borger, D. R.
    Iafrate, A. J.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    BRITISH JOURNAL OF CANCER, 2014, 111 (03) : 430 - 436
  • [50] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
    A F Hezel
    M S Noel
    J N Allen
    T A Abrams
    M Yurgelun
    J E Faris
    L Goyal
    J W Clark
    L S Blaszkowsky
    J E Murphy
    H Zheng
    A A Khorana
    G C Connolly
    O Hyrien
    A Baran
    M Herr
    K Ng
    S Sheehan
    D J Harris
    E Regan
    D R Borger
    A J Iafrate
    C Fuchs
    D P Ryan
    A X Zhu
    British Journal of Cancer, 2014, 111 : 430 - 436
12345